| Immunotherapy in lung cancer: current landscape and future directions H Mamdani, S Matosevic, AB Khalid, G Durm, SI Jalal Frontiers in immunology 13, 823618, 2022 | 134 | 2022 |
| Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO living guideline N Singh, S Temin, S Baker Jr, E Blanchard, JR Brahmer, P Celano, ... Journal of Clinical Oncology 40 (28), 3323-3343, 2022 | 115 | 2022 |
| Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States R Jinjuvadia, S Liangpunsakul Journal of Clinical Gastroenterology 49 (6), 506-511, 2015 | 92 | 2015 |
| Characterization of KRAS mutation subtypes in non–small cell lung cancer J Judd, N Abdel Karim, H Khan, AR Naqash, Y Baca, J Xiu, ... Molecular cancer therapeutics 20 (12), 2577-2584, 2021 | 89 | 2021 |
| Novel therapies in small cell lung cancer H Mamdani, R Induru, SI Jalal Translational lung cancer research 4 (5), 533, 2015 | 75 | 2015 |
| Blood-based tumor biomarkers in lung cancer for detection and treatment H Mamdani, S Ahmed, S Armstrong, T Mok, SI Jalal Translational Lung Cancer Research 6 (6), 648, 2017 | 72 | 2017 |
| Histone deacetylase inhibition in non-small cell lung cancer: hype or hope? H Mamdani, SI Jalal Frontiers in cell and developmental biology 8, 582370, 2020 | 60 | 2020 |
| Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies M Johnson, A El-Khoueiry, N Hafez, N Lakhani, H Mamdani, J Rodon, ... Clinical Cancer Research 27 (16), 4521-4530, 2021 | 37 | 2021 |
| Excellent Response to Anti-PD1 therapy in a Patient with Hepatocellular Carcinoma: Case Report and Review of Literature H Mamdani, H Wu, BH O'Neil, A Sehdev Discovery Medicine, 2017 | 34 | 2017 |
| Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer D Modi, C Hwang, H Mamdani, S Kim, H Gayar, U Vaishampayan, ... Clinical genitourinary cancer 14 (5), 373-380. e2, 2016 | 29 | 2016 |
| Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other … ML Johnson, GK Dy, H Mamdani, A Dowlati, AJ Schoenfeld, JM Pacheco, ... Journal of Clinical Oncology 40 (16_suppl), 8566-8566, 2022 | 25 | 2022 |
| Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors A Tolcher, H Mamdani, P Chalasani, F Meric-Bernstam, M Gazdoiu, ... Cancer Research 81 (13_Supplement), CT016-CT016, 2021 | 20 | 2021 |
| Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2 DH Owen, N Singh, N Ismaila, E Blanchard, P Celano, N Florez, D Jain, ... Journal of Clinical Oncology 41 (5), e10-e20, 2023 | 19 | 2023 |
| A phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: a big ten cancer research … H Mamdani, B Schneider, SM Perkins, HN Burney, PM Kasi, LI Abushahin, ... Frontiers in Oncology 11, 736620, 2021 | 19 | 2021 |
| Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16 … GA Durm, H Mamdani, SK Althouse, SK Jabbour, AK Ganti, SI Jalal, ... Journal of Clinical Oncology 40 (16_suppl), 8509-8509, 2022 | 17 | 2022 |
| Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis CM Bestvina, JG Whisenant, V Torri, A Cortellini, H Wakelee, S Peters, ... JTO Clinical and Research Reports 3 (8), 100335, 2022 | 15 | 2022 |
| The effects of HER2 alterations in EGFR mutant non-small cell lung cancer M Nagasaka, V Singh, Y Baca, A Sukari, C Kim, H Mamdani, AI Spira, ... Clinical lung cancer 23 (1), 52-59, 2022 | 15 | 2022 |
| Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from … M Yan, GA Durm, H Mamdani, V Ernani, SK Jabbour, J Naidoo, ... Journal of Clinical Oncology 38 (15_suppl), 9010-9010, 2020 | 15 | 2020 |
| Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO living guideline, version 2023.1 N Singh, IA Jaiyesimi, N Ismaila, NB Leighl, H Mamdani, T Phillips, ... Journal of Clinical Oncology 41 (15), e51-e62, 2023 | 14 | 2023 |
| CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer ML Johnson, AB El-Khoueiry, N Hafez, NJ Lakhani, H Mamdani, ... J. Clin. Oncol 38 (3502), 10.1200, 2020 | 14 | 2020 |
unnikrishnan pillaiNephrology, Indiana University Ball Memorial Hospital,IndianaVerified email at ipc-hub.com
